Muscle allograft survival after cyclosporin A immunosuppression

Adarsh K Gulati, Andrew A. Zalewski

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

In normal rats, autografts of skeletal muscle survive, whereas allografts of muscle are immunologically rejected. In the present study we sought to determine whether or not the new immunosuppressive drug cyclosporin A (CyA) would prevent the rejection of muscle allografts. Autografts and allografts of rat extensor digitorum longus muscles were made into recipients that went untreated (i.e., no treatment or vehicle injected) or that received daily injections of CyA (5 mg/kg). Autografts of muscle survived throughout the 12-week period of study. On the other hand, untreated rats rejected muscle allografts within 2 weeks, whereas allografts in CyA-treated recipients survived, even at 12 weeks when the experiment was terminated. In another study, CyA therapy was discontinued after 4 weeks in rats that received bilateral muscle allografts, both of which had survived; one was removed at that time. The second muscle allograft from these rats was examined 2 months later, and all were found rejected. CyA was also effective in preventing the rejection of muscle allografts in rats that were previously sensitized to the same transplantation antigens present on the allogeneic muscle cells. These results demonstrated that CyA can prevent the rejection of muscle allografts but only if drug treatment is continued. We conclude that CyA is a potent immunosuppressive agent which could prove useful in clinical muscle allotransplantation or in experimental animal studies that require immunosuppression.

Original languageEnglish (US)
Pages (from-to)378-385
Number of pages8
JournalExperimental Neurology
Volume77
Issue number2
DOIs
StatePublished - Jan 1 1982
Externally publishedYes

Fingerprint

Immunosuppression
Cyclosporine
Allografts
Muscles
Autografts
Immunosuppressive Agents
Histocompatibility Antigens
Pharmaceutical Preparations
Muscle Cells
Skeletal Muscle
Therapeutics
Injections

ASJC Scopus subject areas

  • Neurology
  • Developmental Neuroscience

Cite this

Muscle allograft survival after cyclosporin A immunosuppression. / Gulati, Adarsh K; Zalewski, Andrew A.

In: Experimental Neurology, Vol. 77, No. 2, 01.01.1982, p. 378-385.

Research output: Contribution to journalArticle

Gulati, Adarsh K ; Zalewski, Andrew A. / Muscle allograft survival after cyclosporin A immunosuppression. In: Experimental Neurology. 1982 ; Vol. 77, No. 2. pp. 378-385.
@article{205972194bd24c83a407fc71ddedebe8,
title = "Muscle allograft survival after cyclosporin A immunosuppression",
abstract = "In normal rats, autografts of skeletal muscle survive, whereas allografts of muscle are immunologically rejected. In the present study we sought to determine whether or not the new immunosuppressive drug cyclosporin A (CyA) would prevent the rejection of muscle allografts. Autografts and allografts of rat extensor digitorum longus muscles were made into recipients that went untreated (i.e., no treatment or vehicle injected) or that received daily injections of CyA (5 mg/kg). Autografts of muscle survived throughout the 12-week period of study. On the other hand, untreated rats rejected muscle allografts within 2 weeks, whereas allografts in CyA-treated recipients survived, even at 12 weeks when the experiment was terminated. In another study, CyA therapy was discontinued after 4 weeks in rats that received bilateral muscle allografts, both of which had survived; one was removed at that time. The second muscle allograft from these rats was examined 2 months later, and all were found rejected. CyA was also effective in preventing the rejection of muscle allografts in rats that were previously sensitized to the same transplantation antigens present on the allogeneic muscle cells. These results demonstrated that CyA can prevent the rejection of muscle allografts but only if drug treatment is continued. We conclude that CyA is a potent immunosuppressive agent which could prove useful in clinical muscle allotransplantation or in experimental animal studies that require immunosuppression.",
author = "Gulati, {Adarsh K} and Zalewski, {Andrew A.}",
year = "1982",
month = "1",
day = "1",
doi = "10.1016/0014-4886(82)90251-5",
language = "English (US)",
volume = "77",
pages = "378--385",
journal = "Experimental Neurology",
issn = "0014-4886",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Muscle allograft survival after cyclosporin A immunosuppression

AU - Gulati, Adarsh K

AU - Zalewski, Andrew A.

PY - 1982/1/1

Y1 - 1982/1/1

N2 - In normal rats, autografts of skeletal muscle survive, whereas allografts of muscle are immunologically rejected. In the present study we sought to determine whether or not the new immunosuppressive drug cyclosporin A (CyA) would prevent the rejection of muscle allografts. Autografts and allografts of rat extensor digitorum longus muscles were made into recipients that went untreated (i.e., no treatment or vehicle injected) or that received daily injections of CyA (5 mg/kg). Autografts of muscle survived throughout the 12-week period of study. On the other hand, untreated rats rejected muscle allografts within 2 weeks, whereas allografts in CyA-treated recipients survived, even at 12 weeks when the experiment was terminated. In another study, CyA therapy was discontinued after 4 weeks in rats that received bilateral muscle allografts, both of which had survived; one was removed at that time. The second muscle allograft from these rats was examined 2 months later, and all were found rejected. CyA was also effective in preventing the rejection of muscle allografts in rats that were previously sensitized to the same transplantation antigens present on the allogeneic muscle cells. These results demonstrated that CyA can prevent the rejection of muscle allografts but only if drug treatment is continued. We conclude that CyA is a potent immunosuppressive agent which could prove useful in clinical muscle allotransplantation or in experimental animal studies that require immunosuppression.

AB - In normal rats, autografts of skeletal muscle survive, whereas allografts of muscle are immunologically rejected. In the present study we sought to determine whether or not the new immunosuppressive drug cyclosporin A (CyA) would prevent the rejection of muscle allografts. Autografts and allografts of rat extensor digitorum longus muscles were made into recipients that went untreated (i.e., no treatment or vehicle injected) or that received daily injections of CyA (5 mg/kg). Autografts of muscle survived throughout the 12-week period of study. On the other hand, untreated rats rejected muscle allografts within 2 weeks, whereas allografts in CyA-treated recipients survived, even at 12 weeks when the experiment was terminated. In another study, CyA therapy was discontinued after 4 weeks in rats that received bilateral muscle allografts, both of which had survived; one was removed at that time. The second muscle allograft from these rats was examined 2 months later, and all were found rejected. CyA was also effective in preventing the rejection of muscle allografts in rats that were previously sensitized to the same transplantation antigens present on the allogeneic muscle cells. These results demonstrated that CyA can prevent the rejection of muscle allografts but only if drug treatment is continued. We conclude that CyA is a potent immunosuppressive agent which could prove useful in clinical muscle allotransplantation or in experimental animal studies that require immunosuppression.

UR - http://www.scopus.com/inward/record.url?scp=0019944342&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019944342&partnerID=8YFLogxK

U2 - 10.1016/0014-4886(82)90251-5

DO - 10.1016/0014-4886(82)90251-5

M3 - Article

C2 - 7095065

AN - SCOPUS:0019944342

VL - 77

SP - 378

EP - 385

JO - Experimental Neurology

JF - Experimental Neurology

SN - 0014-4886

IS - 2

ER -